Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of 3 versus 6 cycles of neoadjuvant carboplatin-paclitaxel in advanced ovarian, fallopian tube, or primary peritoneal cancer
2013-002520-17Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Oct 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Rate of complete cytoreductive surgery. Started Oct 2013; status: completed.
02
Drugs
carboplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2013-002520-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002520-17.